Targetable MYH9 gene drives cancer progression and inherited genetic disorders

A comprehensive new review article highlights the growing importance of the MYH9 gene as a central player in both cancer biology and inherited genetic conditions, offering fresh perspectives on its potential as a therapeutic target.

The MYH9 gene encodes non-muscle myosin IIA (NMIIA), a critical protein responsible for essential cellular functions such as cell movement, division, and signal transmission. These fundamental roles position MYH9 at the heart of cellular behavior, making it increasingly relevant in understanding disease mechanisms.

Recent attention has focused on MYH9's involvement in cancer progression, where it demonstrates a complex and sometimes dual nature, acting either as an oncogene or a tumor suppressor depending on the biological context. Its influence extends to key processes such as tumor growth, metastasis, and treatment resistance, underscoring its significance in shaping disease outcomes.

In parallel, MYH9 is known for its role in a group of inherited conditions collectively termed MYH9-related diseases (MYH9-RD). These disorders are characterized by features such as thrombocytopenia, hearing loss, and kidney complications, reflecting the gene's wide-ranging impact across multiple organ systems.

A particularly intriguing aspect of MYH9 biology is its interaction with non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs. These molecules regulate MYH9 expression and activity, influencing pathways linked to cancer initiation, progression, and metastasis. This regulatory network adds another layer of complexity and opens new avenues for targeted intervention.

Emerging therapeutic strategies are beginning to focus on MYH9 through approaches such as small-molecule inhibitors, RNA-based therapies, and gene-editing technologies. These strategies aim to disrupt the molecular pathways associated with MYH9, potentially improving treatment outcomes in a range of malignancies.

Despite these advances, key questions remain, particularly regarding whether individuals with MYH9 mutations may have altered susceptibility to cancer. This unresolved issue highlights the need for continued investigation into the gene's dual roles in disease.

Overall, the expanding understanding of MYH9 structure, function, and clinical relevance positions it as a promising focal point in modern biomedical research, with significant implications for the future of precision medicine and targeted cancer therapy.